Effects of the SGLT2-inhibitor empagliflozin in patients with chronic syndrome of inadequate antidiuresis (SIAD) - results of a double-blind, randomized, placebo-controlled, crossover trial
Endocrine Abstracts · 07.05.2022
DOI: 10.1530/endoabs.81.p165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Abstracts, online erschienen am 07.05.2022. Verfasst von Julie Refardt und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Refardt, J., Imber, C., Nobbenhuis, R., Clara, O. S., Haslbauer, A., Vogt, D., Berres, M., Winzeler, B., Bridenbaugh, S., & Mirjam, C. (2022). Effects of the SGLT2-inhibitor empagliflozin in patients with chronic syndrome of inadequate antidiuresis (SIAD) - results of a double-blind, randomized, placebo-controlled, crossover trial. Endocrine Abstracts. https://doi.org/10.1530/endoabs.81.p165
Vancouver
Refardt J, Imber C, Nobbenhuis R, Clara OS, Haslbauer A, Vogt D, et al. Effects of the SGLT2-inhibitor empagliflozin in patients with chronic syndrome of inadequate antidiuresis (SIAD) - results of a double-blind, randomized, placebo-controlled, crossover trial. Endocrine Abstracts. 2022. doi:10.1530/endoabs.81.p165
BibTeX
@article{Refardt2022,
author = {Refardt, Julie and Imber, Cornelia and Nobbenhuis, Rianne and Clara, Odilia Sailer and Haslbauer, Aaron and Vogt, Deborah and Berres, Manfred and Winzeler, Bettina and Bridenbaugh, Stephanie and Mirjam, Christ-Crain},
title = {Effects of the SGLT2-inhibitor empagliflozin in patients with chronic syndrome of inadequate antidiuresis (SIAD) - results of a double-blind, randomized, placebo-controlled, crossover trial},
journal = {Endocrine Abstracts},
year = {2022},
doi = {10.1530/endoabs.81.p165}
}
EUVIMED